Impact of diabetes on platelet activation in different manifestations of atherosclerosis

Swiss Medical Weekly

Volumn 143, Issue , 2013, Pages

  Gremmel, Thomas ^a   Kopp, Christoph W ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Steiner, Sabine ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Diabetes; Platelet activation; Thrombin

Indexed keywords

PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; PEPTIDE FRAGMENT; THROMBIN RECEPTOR PEPTIDE (42 47); THROMBIN RECEPTOR PEPTIDE (42-47);

ADULT; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; PROTEIN EXPRESSION; STENT; THROMBOCYTE; THROMBOCYTE ACTIVATION; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; CYTOLOGY; DRUG EFFECT; IN VITRO STUDY; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; COMPLICATION; DRUG EFFECTS;

ADULT; AGED; ATHEROSCLEROSIS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PERIPHERAL ARTERIAL DISEASE; PLATELET ACTIVATION; RECEPTOR, PAR-1; IN VITRO TECHNIQUES;

EID: 84878393928     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2013.13800     Document Type: Article

References (39)

1. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527-32. (Pubitemid 37176462)
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA. 2002;287:2570-81. (Pubitemid 34517204)
3. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol. 1992;45:1327-34.
4. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation. 1993;88:837-45. (Pubitemid 23263998)
5. Fabris F, Zanocchi M, Bo M, Fonte G, Poli L, Bergoglio I, et al. Carotid plaque, aging, and risk factors. A study of 457 subjects. Stroke. 1994;25:1133-40.
6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34. (Pubitemid 28350165)
7. Diabetes-related amputations of lower extremities in the Medicare population- Minnesota, 1993-1995. MMWR Morb Mortal Wkly Rep. 1998;47:649-52.
8. Folsom AR, Rasmussen ML, Chambless LE, Howard G, Cooper LS, Schmidt MI, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care. 1999;22:1077-83. (Pubitemid 29293959)
9. Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost. 1992;68:577-82.
10. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44:188-95. (Pubitemid 32156203)
11. Ay L, Kopp HP, Brix JM, Ay C, Quehenberger P, Schernthaner GH, et al. Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost. 2010;8:759-65.
12. Hong YJ, Jeong MH, Choi YH, Song JA, Kim DH, Lee KH, et al. Impact of diabetes mellitus on plaque vulnerability and clinical outcome in patients with acute myocardial infarction with plaque rupture. Int J Cardiol. 2012;154:197-8.
13. McEver RP. Selectins. Current opinion in immunology. 1994;6:75-84. (Pubitemid 24050709)
14. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med. 1992;175:1147-50.
15. Michelson AD and Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999;6:342-8.
16. Stellos K, Bigalke B, Stakos D, Henkelmann N, Gawaz M. Plateletbound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J Thromb Haemost. 2010;8:205-7.
17. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998;31:352-8. (Pubitemid 28153455)
18. Leger AJ, Covic L and Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114:1070-7. (Pubitemid 44358884)
19. Dormann D, Clemetson KJ and Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood. 2000;96:2469-78.
20. Jurk K, Jahn UR, Van Aken H, Schriek C, Droste DW, Ritter MA, et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost. 2004;91:334-44. (Pubitemid 38240180)
21. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282-91. (Pubitemid 40186123)
22. Liani R, Halvorsen B, Sestili S, Handberg A, Santilli F, Vazzana N, et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free radical biology & medicine. 2012;52:1318-24.
23. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest. 2004;34:205-9. (Pubitemid 38406635)
24. Yngen M, Norhammar A, Hjemdahl P, Wallen NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diabetes & vascular disease research: official journal of the International Society of Diabetes and Vascular Disease. 2006;3:52-6. (Pubitemid 43877254)
25. Eslam RB, Reiter N, Kaider A, Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J. 2009;30:1831-6.
26. Gremmel T, Eslam RB, Koppensteiner R, Lang IM, Panzer S. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovasc Ther. 2013; Epub ahead of print.
27. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2002;23:1771-9. (Pubitemid 35334270)
28. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, et al. Aspirin "resistance": role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008;6:2035-44.
29. Frelinger AL 3rd, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011;106:219-26.
30. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51:1588-96. (Pubitemid 351509419)
31. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533-7. (Pubitemid 32917347)
32. Ishida M, Ishida T, Ono N, Matsuura H, Watanabe M, Kajiyama G, et al. Effects of insulin on calcium metabolism and platelet aggregation. Hypertension. 1996;28:209-12. (Pubitemid 26322791)
33. Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121-6. (Pubitemid 28030398)
34. Matsuno H, Tokuda H, Ishisaki A, Zhou Y, Kitajima Y, Kozawa O. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. The Journal of clinical endocrinology and metabolism. 2005;90:920-7. (Pubitemid 40279217)
35. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:743-9.
36. Schafer A and Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Current vascular pharmacology. 2008;6:52-60.
37. Jardin I, Redondo PC, Salido GM, Pariente JA, Rosado JA. Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus. Platelets. 2006;17:283-8. (Pubitemid 44277692)
38. Anfossi G, Russo I and Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis. 2009;19:440-9.
39. Lim HS, Blann AD and Lip GY. Soluble CD40 ligand, soluble Pselectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109:2524-8. (Pubitemid 38720551)